Peripheral Blood Mononuclear Cells Profiling Revealed Biomarkers That Predict PD‐1 Inhibitor‐Induced Immune‐Related Adverse Events
MedComm · 2026-04 · 7 (4)
DOI: 10.1002/mco2.70721 ↗Kurz gefasst
Fachartikel in der Zeitschrift MedComm, online erschienen am 05.04.2026. Verfasst von Jun Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital Jinan China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Key Laboratory of Molecular Imaging, ShanghaiTech University, Natural Science Foundation of Shandong Province.
Themen: Patientensicherheit
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) universally enhance antitumor immunity but endanger a subgroup of patients by triggering immune‐related adverse events (irAEs). We profiled the expressions of 41 proteins on peripheral blood mononuclear cells (PBMCs) prior the initiation of immunotherapy. CXCR3 and CCR6 expressions were significantly decreased in PBMC subpopulations from patient with irAEs but not from those who responded to PD‐1 inhibitors. The expression of CCR6 in a NK cell subpopulation serves exclusively as a biomarker to differentiate patients who developed irAEs. Interestingly, circulating ligands of CXCR3, including CXCL9, CXCL10, and CXCL11, were significantly increased in patients who later developed irAEs after PD‐1 inhibitor treatment. The decreases of CXCR3 in three T cell subpopulations and decreases of CCR6 in a NK cell subpopulation were further validated in two independent external cohorts. Moreover, multiple proteins in PBMCs, distinct from the irAE‐predicting biomarkers, exhibited differential expression levels corresponding to the differential responses to the PD‐1 inhibitors. Via multiple independent cohorts, our study revealed crucial roles of CXCR3 and CCR6 in PD‐1‐induced irAEs, provided potential circulating biomarkers associated with toxicity and responses of PD‐1 inhibitors and further sculptured the landscape of immune cell heterogeneity via focusing on PBMC subpopulations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital Jinan China.
- Shandong Lung Cancer Institute The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital Jinan China.
- Lung Cancer Center The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital Jinan China.
- Shanghai Key Laboratory of Molecular Imaging Pudong Gongli Hospital Shanghai University of Medicine and Health Sciences Shanghai China.
- Shanghai Institute for Advanced Immunochemical Studies ShanghaiTech University Shanghai China.
- The Second Department of Thoracic Oncology The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital Changsha China.
ORCID-Profile: Chen Wang
Förderung
- Shanghai Key Laboratory of Molecular Imaging
- ShanghaiTech University
- Natural Science Foundation of Shandong Province
Zitieren
APA
Wang, J., Xie, H., Gong, Y., Liu, S., Guan, Y., Zhang, Y., Xie, Q., Wang, J., Li, Y., Zeng, X., Chen, X., & Wang, C. (2026). Peripheral Blood Mononuclear Cells Profiling Revealed Biomarkers That Predict PD‐1 Inhibitor‐Induced Immune‐Related Adverse Events. MedComm, 7(4). https://doi.org/10.1002/mco2.70721
Vancouver
Wang J, Xie H, Gong Y, Liu S, Guan Y, Zhang Y, et al. Peripheral Blood Mononuclear Cells Profiling Revealed Biomarkers That Predict PD‐1 Inhibitor‐Induced Immune‐Related Adverse Events. MedComm. 2026;7(4). doi:10.1002/mco2.70721
BibTeX
@article{Wang2026,
author = {Wang, Jun and Xie, Hong and Gong, Yuanyuan and Liu, Songlin and Guan, Yaping and Zhang, Yuekai and Xie, Qi and Wang, Jingyi and Li, Ye and Zeng, Xueqin and Chen, Xi and Wang, Chen},
title = {Peripheral Blood Mononuclear Cells Profiling Revealed Biomarkers That Predict PD‐1 Inhibitor‐Induced Immune‐Related Adverse Events},
journal = {MedComm},
year = {2026},
volume = {7},
number = {4},
doi = {10.1002/mco2.70721}
}
EUVIMED